Carbamylation is a competitor of glycation for protein modification in vivo.
Fiche publication
Date publication
juillet 2017
Journal
Diabetes & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GILLERY Philippe
Tous les auteurs :
Nicolas C, Jaisson S, Gorisse L, Tessier FJ, Niquet-Léridon C, Jacolot P, Pietrement C, Gillery P
Lien Pubmed
Résumé
Chronic kidney disease (CKD) and diabetes mellitus are two diseases that accelerate protein molecular ageing through carbamylation and glycation reactions, characterized by the binding of urea-derived isocyanic acid and of sugars on proteins, respectively. These two reactions target the same protein amino groups and, thus, compete with each other. Such competition may arise especially in diabetic patients with nephropathy. This study aimed to evaluate their potential competitive effects in vitro and under conditions reproducing CKD and/or diabetes in vivo.
Mots clés
Carbamylation, Chronic kidney disease, Competition, Diabetes mellitus, Glycation, HbA(1c)
Référence
Diabetes Metab.. 2017 Jul;: